Loading…
← CockpitCompetitor Analysis › AURA Aura Biosciences IncOpen in the cockpit ↗

Aura Biosciences IncAURACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum neutral 53
Mkt cap
$743M
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$5.24M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.1%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · USD$7.14
1D-0.1%
1W-6.2%
1M+8.8%
3M-8.1%
6M-4.4%
YTD+31.0%
1Y+29.8%
ATR %5.3%
Beta1.15
52w lowhigh25.1% off high

What Aura Biosciences does

Employees: 113

Aura Biosciences at a glance

Size Aura Biosciences (AURA) is a United States Health Care company (Biotechnology) with a market value of $743M, the 2421st largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.14 on 18 Nov 2026.

Performance Over six months the shares fell 4.4%, against -22.2% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 19 in its peer set.

Short interest Short interest is 10.1% of the free float (30 Oct 2026).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026AURA 93Peer median 78
Six months, rebased to 100: Aura Biosciences against the median of its 20 peers (local-currency closes).

Aura Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$1.15M-$1.13M-$1.22M-$1.29M-$1.18M
EBITDA-$144M-$112M-$94.9M-$83.7M-$59.1M
Net income-$137M-$106M-$86.9M-$76.4M-$58.8M
Free cash flow-$110M-$85.2M-$81.1M-$64.6M-$55.7M
Capital expenditure$379,000$447,000$1.25M$709,000$1.09M
Total debt$16.2M$17.4M$18.8M$19.6M$20.9M

Quarterly statements and history in the cockpit →

Aura Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%002038IVA9887301333SNDXGLUEATTOMGTX7729AURA6-month return →1-month return →
Up and to the right = strong over both horizons. Aura Biosciences is the large dot.

Aura Biosciences competitors and peer comparison

How Aura Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aura Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureAURAPeer medianRank in peer set
1-month return+8.8%-6.9%3rd highest of 21
6-month return-4.4%-22.2%6th highest of 19
Distance from 52-week high-25.1%-46.5%2nd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a

Questions

Which companies are Aura Biosciences's closest peers?
The cockpit's peer set: Beijing SL Pharmaceutical (002038.SZ), Apnimed (APMD), Inventiva (IVA.PA), Nanjing Leads Biolabs (9887.HK), R&G PharmaStudies (301333.SZ), Syndax Pharmaceuticals (SNDX), Shaanxi Micot Pharmaceutical Technology (2335.HK), Monte Rosa Therapeutics (GLUE).
How has Aura Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -4.4% against -22.2% for the median peer; over one year +29.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.